GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

South Korea’s pharma industry has a valuable pool of promising drugs, but China still leads the way in out-licensing deals.

HHS Secretary Robert F. Kennedy Jr, is a well-known vaccine critic, but it is way past time for human health to be put on a ...

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for ...

In July 2025, Mersana made a payment of approximately $17.9 million to satisfy in full its indebtedness and obligations under the company’s previous loan and security agreement. The company continues ...

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero ...

A powerful wave of optimism continued to wash over global markets on Wednesday, propelling European equities higher as ...

The S&P 500 rose 1.1% to peak at 6,445 while the tech-focused Nasdaq Composite surged 1.4% to a new record. The Dow Jones ...

GSK plc announced the acquisition of ordinary shares by several key executives under the Company’s Share Reward Plan. This transaction, conducted on the London Stock Exchange, involved the purchase of ...

After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month ...

(Alliance News) - British Land Co PLC on Wednesday said it signed nine new UK-based biotech and health tech startups for its new co-working lab space adjacent to Regent's Place.

Theravance Biopharma's Q2 2025 earnings show robust growth with YUPELRI sales up 22%, a $225M TRELEGY royalty sale, and progress in the pivotal CYPRESS trial.